Thrombocytopenia - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 167 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Thrombocytopenia - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Thrombocytopenia - Pipeline Review, H2 2015', provides an overview of the Thrombocytopenia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Thrombocytopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocytopenia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Thrombocytopenia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Thrombocytopenia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Thrombocytopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Thrombocytopenia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Thrombocytopenia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Thrombocytopenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Thrombocytopenia Overview 11
Therapeutics Development 12
Pipeline Products for Thrombocytopenia - Overview 12
Pipeline Products for Thrombocytopenia - Comparative Analysis 13
Thrombocytopenia - Therapeutics under Development by Companies 14
Thrombocytopenia - Therapeutics under Investigation by Universities/Institutes 16
Thrombocytopenia - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Thrombocytopenia - Products under Development by Companies 20
Thrombocytopenia - Products under Investigation by Universities/Institutes 23
Thrombocytopenia - Companies Involved in Therapeutics Development 24
3SBio Inc. 24
Amarillo Biosciences, Inc. 25
Amgen Inc. 26
Arcturus Therapeutics, Inc 27
aTyr Pharma, Inc. 28
Baxalta Incorporated 29
Bayer AG 30
BioLineRx, Ltd. 31
Boehringer Ingelheim GmbH 32
Bolder Biotechnology, Inc. 33
Bristol-Myers Squibb Company 34
Cellerant Therapeutics, Inc. 35
Eisai Co., Ltd. 36
Hansa Medical AB 37
Immunomedics, Inc. 38
Intas Pharmaceuticals Ltd. 39
Jiangsu Hengrui Medicine Co., Ltd. 40
Merck & Co., Inc. 41
Momenta Pharmaceuticals, Inc. 42
Myelo Therapeutics GmbH 43
Neumedicines Inc. 44
Novartis AG 45
Pfizer Inc. 46
PhytoHealth Corporation 47
Prophylix Pharma AS 48
Protalex, Inc. 49
Rigel Pharmaceuticals, Inc. 50
Shionogi & Co., Ltd. 51
STATegics, Inc. 52
ViroMed Co., Ltd. 53
Thrombocytopenia - Therapeutics Assessment 54
Assessment by Monotherapy Products 54
Assessment by Target 55
Assessment by Mechanism of Action 57
Assessment by Route of Administration 59
Assessment by Molecule Type 61
Drug Profiles 63
Antibody for Autoimmune Disorders and Inflammation - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
avatrombopag - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
BBT-059 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
BI-655064 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
BL-8040 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
BMS-986004 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
CLT-009 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
eltrombopag olamine - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
eltrombopag olamine - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
fostamatinib disodium - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
GL-2045 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
GSK-2285921 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Hetrombopag Olamine - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
interferon alfa - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
LUNAR-TPO - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
lusutrombopag - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
MK-8723 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Monoclonal Antibody to Agonize TpoR for Thrombocytopenia - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Monoclonal Antibody to Antagonize FcgR1 for Inflammatory and Autoimmune Disorders - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Monoclonal Antibody to Antagonize FcgRIIa for Inflammatory and Autoimmune Disorders - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Myelo-001 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
NMIL-121 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Oligonucleotides to Activate miRNA-150 for Thrombocytopenia - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
PBF-1509 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
PEG-VM501 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
PHN-013 - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
PRTX-100 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Recombinant Enzyme to Inhibit Immunoglobulin G for Autoimmune Diseases - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
rivaroxaban - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
romiplostim - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
romiplostim biosimilar - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
SM-101 - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Small Molecules to Inhibit BLVRB for Thrombocytopenia - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
Small Molecules to Inhibit PF4 for HIT - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
STST-4 - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
Tmax - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
Tromplate - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
TXA-302 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
veltuzumab - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
Thrombocytopenia - Recent Pipeline Updates 124
Thrombocytopenia - Dormant Projects 155
Thrombocytopenia - Discontinued Products 157
Thrombocytopenia - Product Development Milestones 158
Featured News & Press Releases 158
Sep 08, 2015: Rigel Granted Orphan Drug Designation for Fostamatinib in ITP 158
Sep 04, 2015: Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 158
Aug 24, 2015: FDA expands use of Novartis drug Promacta to include treatment of children ages 1 and older with chronic immune thrombocytopenia 159
Aug 04, 2015: Immunomedics Announces Orphan Drug Designation for Veltuzumab for the Treatment of Immune Thrombocytopenia 160
Jun 12, 2015: FDA Approves Promacta for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication 161
Jun 11, 2015: Novartis gains FDA approval for Promacta providing new option for children, ages 6 and older, with chronic ITP, a rare blood disorder 162
May 27, 2015: Amgen To present data from Nplate study at the 20th Congress of the EHA 163
May 11, 2015: Xarelto Bleeding Lawsuit Judge Orders the Selection of Cases for Discovery, Reports Xarelto Lawsuit Funding Firm, Fair Rate Funding 164
Feb 06, 2015: GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade) 165
Dec 22, 2014: GSK announces US regulatory submission seeking additional indication for eltrombopag (Promacta) 165
Appendix 166
Methodology 166
Coverage 166
Secondary Research 166
Primary Research 166
Expert Panel Validation 166
Contact Us 166
Disclaimer 167

List of Tables

Number of Products under Development for Thrombocytopenia, H2 2015 12
Number of Products under Development for Thrombocytopenia - Comparative Analysis, H2 2015 13
Number of Products under Development by Companies, H2 2015 15
Number of Products under Investigation by Universities/Institutes, H2 2015 16
Comparative Analysis by Late Stage Development, H2 2015 17
Comparative Analysis by Clinical Stage Development, H2 2015 18
Comparative Analysis by Early Stage Development, H2 2015 19
Products under Development by Companies, H2 2015 20
Products under Development by Companies, H2 2015 (Contd..1) 21
Products under Development by Companies, H2 2015 (Contd..2) 22
Products under Investigation by Universities/Institutes, H2 2015 23
Thrombocytopenia - Pipeline by 3SBio Inc., H2 2015 24
Thrombocytopenia - Pipeline by Amarillo Biosciences, Inc., H2 2015 25
Thrombocytopenia - Pipeline by Amgen Inc., H2 2015 26
Thrombocytopenia - Pipeline by Arcturus Therapeutics, Inc, H2 2015 27
Thrombocytopenia - Pipeline by aTyr Pharma, Inc., H2 2015 28
Thrombocytopenia - Pipeline by Baxalta Incorporated, H2 2015 29
Thrombocytopenia - Pipeline by Bayer AG, H2 2015 30
Thrombocytopenia - Pipeline by BioLineRx, Ltd., H2 2015 31
Thrombocytopenia - Pipeline by Boehringer Ingelheim GmbH, H2 2015 32
Thrombocytopenia - Pipeline by Bolder Biotechnology, Inc., H2 2015 33
Thrombocytopenia - Pipeline by Bristol-Myers Squibb Company, H2 2015 34
Thrombocytopenia - Pipeline by Cellerant Therapeutics, Inc., H2 2015 35
Thrombocytopenia - Pipeline by Eisai Co., Ltd., H2 2015 36
Thrombocytopenia - Pipeline by Hansa Medical AB, H2 2015 37
Thrombocytopenia - Pipeline by Immunomedics, Inc., H2 2015 38
Thrombocytopenia - Pipeline by Intas Pharmaceuticals Ltd., H2 2015 39
Thrombocytopenia - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2015 40
Thrombocytopenia - Pipeline by Merck & Co., Inc., H2 2015 41
Thrombocytopenia - Pipeline by Momenta Pharmaceuticals, Inc., H2 2015 42
Thrombocytopenia - Pipeline by Myelo Therapeutics GmbH, H2 2015 43
Thrombocytopenia - Pipeline by Neumedicines Inc., H2 2015 44
Thrombocytopenia - Pipeline by Novartis AG, H2 2015 45
Thrombocytopenia - Pipeline by Pfizer Inc., H2 2015 46
Thrombocytopenia - Pipeline by PhytoHealth Corporation, H2 2015 47
Thrombocytopenia - Pipeline by Prophylix Pharma AS, H2 2015 48
Thrombocytopenia - Pipeline by Protalex, Inc., H2 2015 49
Thrombocytopenia - Pipeline by Rigel Pharmaceuticals, Inc., H2 2015 50
Thrombocytopenia - Pipeline by Shionogi & Co., Ltd., H2 2015 51
Thrombocytopenia - Pipeline by STATegics, Inc., H2 2015 52
Thrombocytopenia - Pipeline by ViroMed Co., Ltd., H2 2015 53
Assessment by Monotherapy Products, H2 2015 54
Number of Products by Stage and Target, H2 2015 56
Number of Products by Stage and Mechanism of Action, H2 2015 58
Number of Products by Stage and Route of Administration, H2 2015 60
Number of Products by Stage and Molecule Type, H2 2015 62
Thrombocytopenia Therapeutics - Recent Pipeline Updates, H2 2015 124
Thrombocytopenia - Dormant Projects, H2 2015 155
Thrombocytopenia - Dormant Projects (Contd..1), H2 2015 156
Thrombocytopenia - Discontinued Products, H2 2015 157